Song Bo, Duan Zhong-Yu, Zhong Yun-Hua, Lei Na, Yang Yu-Qing, Luo Kai-Yuan
Department of General Surgery, The Fourth Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China E-mail :
Asian Pac J Cancer Prev. 2014 Jan;14(11):6649-51. doi: 10.7314/apjcp.2013.14.11.6649.
Mdm2 binds to the amino-terminus of p53 to induce its degradation and a single nucleotide polymorphism in the MDM2 promoter region (T309G) has been reported to increase the risk of several carcinomas, such as gastric cancer. However, the results of published studies to analyze the association between MDM2 T309G and gastric cancer havve often conflicted.
To better illustrate the filiation between MDM2 T309G and gastric cancer, we performed a meta-analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the relationship. The pooled ORs were performed for 4 models, additive, recessive, co-dominant model, and dominant.
Nine published case-control studies including 3,225 gastric cancer cases and 4,118 controls were identified. The MDM2 T309G polymorphism was associated with a significantly increased risk of gastric cancer risk when all studies were pooled into the meta-analysis (GG versus TT, OR=1.57; 95%CI=1.57-2.12; p=0.003) and GG versus GT/TT, OR=1.52; 95%CI=1.217-1.90; p<0.001). Furthermore, Egger<s test did not show any evidence of publication bias (P = 0.608 for GG versus TT).
Our results suggest that the MDM2 T309G polymorphism is indeed associated with a significantly increased risk of gastric cancer.
Mdm2与p53的氨基末端结合以诱导其降解，并且据报道MDM2启动子区域的单核苷酸多态性（T309G）会增加几种癌症的风险，如胃癌。然而，已发表的分析MDM2 T309G与胃癌之间关联的研究结果常常相互矛盾。
为了更好地阐明MDM2 T309G与胃癌之间的关系，我们进行了一项荟萃分析。采用优势比（OR）和95%置信区间（CI）来评估这种关系的强度。对4种模型进行了合并OR分析，即相加模型、隐性模型、共显性模型和显性模型。
共纳入9项已发表的病例对照研究，包括3225例胃癌病例和4118例对照。当所有研究纳入荟萃分析时，MDM2 T309G多态性与胃癌风险显著增加相关（GG与TT相比，OR = 1.57；95%CI = 1.57 - 2.12；p = 0.003），GG与GT/TT相比，OR = 1.52；95%CI = 1.217 - 1.90；p < 0.001。此外，Egger检验未显示任何发表偏倚的证据（GG与TT相比，P = 0.608）。
我们的结果表明，MDM2 T309G多态性确实与胃癌风险显著增加相关。
